Price (delayed)
$1.28
Market cap
$56.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.49
Enterprise value
-$45.22M
AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy
There are no recent dividends present for AVRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.